THERAPY DOSSIER · th-26188b90b91c

Multipotent mesenchymal stromal cells (bone marrow) and human neural stem and progenitor cells

Biologic · Cell therapy; no ChEMBL entity. Multiple human MSC trials registered across indications.

Evidence & regulatory context

Mechanism: Cell therapy; no ChEMBL entity. Multiple human MSC trials registered across indications.
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: MSC; Multipotent mesenchymal stromal cells; Bone marrow MSC; NSPC
Note: Not recorded

Clinical trials 7

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02893306 ↗PHASE2unknown

Phase 2 Study of Intravenous Administration of Allogeneic Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Enrolment: 10 · Results not recorded

NCT02323789 ↗PHASE1/PHASE2unknown

A Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

Enrolment: 10 · Results not recorded

NCT01446614 ↗PHASE1/PHASE2unknown

Phase I/II Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease

Parkinson's Disease

Enrolment: 20 · Results not recorded

NCT00395200 ↗PHASE1/PHASE2completed

Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis

Multiple Sclerosis

Enrolment: 10 · Results not recorded

NCT02209311 ↗PHASE1/PHASE2unknown

Maxilla Alveolar Process Reconstruction Using Tissue Engineered Construction Based on Synthetic Tricalcium Phosphate and Autologous Multipotent Mesenchymal Stromal Cells

Partially Edentulous Maxilla · Alveolar Bone Atrophy · Alveolar Bone Loss

Enrolment: 12 · Results not recorded

NCT02323477 ↗PHASE1/PHASE2terminated

Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction (HUC-HEART)

Chronic Ischemic Cardiomyopathy · Coronary Artery Bypass Surgery

Enrolment: 46 · Results not recorded

NCT02962661 ↗PHASE1suspended

Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells in Anthracycline-Associated Cardiomyopathy

Cardiomyopathy · Heart Failure

Enrolment: 72 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22977876 ↗2012Reported benefit

Neuroprotective effect of mesenchymal and neural stem and progenitor cells on sensorimotor recovery after brain injury.

RatTBIUnspecifiedMaleSystemic administration

Model: Local traumatic brain injury

Both mesenchymal stromal cells and neural stem and progenitor cells promoted recovery of locomotor control and proprioceptive sensitivity and improved survival, with neural stem and progenitor cells also preventing death in delayed periods.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…